PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 125.61K shares, a 88.94% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.14M shares, a 11.45% decline from fiscal 2022.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.28M shares, a 19.41% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 0.00 shares 10-K · filed 2026-02-27 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 0.00 shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 35.89K shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 87.28K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 125.61K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 35.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 163.37K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 51.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 272.63K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 38.34K shares 10-Q · filed 2024-05-08 | 994.17K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 37.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 1.14M shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 145.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 1.67M shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 772.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 2.11M shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 179.47K shares 10-Q · filed 2023-05-04 | 1.37M shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 570.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 1.28M shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 587.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 838.48K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 34.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 543.22K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 89.47K shares 10-Q · filed 2022-05-05 | 933.80K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 127.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | 1.07M shares 10-K · filed 2022-02-25 |
| 2021-09-30 | 292.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 946.66K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 425.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 664.62K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 229.38K shares 10-Q · filed 2021-05-11 | 239.38K shares derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 22.85K shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 10.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | 24.85K shares derived: sum of 4 quarters · filed 2020-11-04 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 14.85K shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | 12.85K shares 10-Q · filed 2020-05-06 | 46.85K shares derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-12-31 | 2.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | 34.85K shares 10-K · filed 2020-03-03 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | 32.85K shares derived: sum of 4 quarters · filed 2019-11-05 |
| 2019-06-30 | 32.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | 64.72K shares derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | 850.00 shares 10-Q · filed 2019-05-07 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | 206.41K shares 10-K · filed 2019-03-15 |
| 2018-09-30 | 31.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | |
| 2014-12-31 | 69.24K shares 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |